TNFRSF8 and anaplastic large cell lymphoma: However, brentuximab vedotin (Adcetris), a targeted anti-CD30 (cluster of differentiation 30) monoclonal antibody-drug conjugate (ADC), was recently introduced for the treatment of HL and ALCL (Younes, 2009; Lymphoma Research Foundation, 2012).